Vapendavir - Altesa Biosceinces/Vaxart
Alternative Names: BTA-798Latest Information Update: 11 Jun 2026
At a glance
- Originator Biota Holdings
- Developer Altesa Biosciences; Aviragen Therapeutics; Vaxart
- Class Antivirals; Benzoxazoles; Ethers; Piperidines; Pyridazines; Small molecules
- Mechanism of Action Capsid protein inhibitors; Rhinovirus replication inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rhinovirus infections
Most Recent Events
- 05 Jun 2026 Efficacy data from a phase IIa challenge trial in Rhinovirus infections released by Altesa BioSciences
- 20 May 2026 Updated efficacy data from a phase IIa trial in Rhinovirus infections presented at the 122nd International Conference of the American Thoracic Society (ATS-2026)
- 19 May 2026 Efficacy and adverse events data from a phase IIa challenge trial in Rhinovirus infections released by Altesa BioSciences